US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novo Nordisk A/S B Shares ADRhedged

25.35

+0.11030.44%

Post-market: 25.350.00000.00%16:15 EDT

Volume:499

Turnover:12.63K

Market Cap:4.06M

PE:- -

High:25.35

Open:25.33

Low:25.33

Close:25.24

52wk High:34.36

52wk Low:19.00

Shares:160.00K

Float Shares:160.00K

Volume Ratio:0.57

T/O Rate:0.31%

Dividend:1.70

Dividend Rate:6.69%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate

Benzinga Earnings

NYSE Most Active Issues

The Wegovy Pill's 'surprise Miss' is One Reason Novo Nordisk's Stock is Down

Wegovy Maker Novo Nordisk Lifts Annual Forecast Amid Rising Demand for Weight-Loss Drugs

Novo Nordisk Raises Earnings Guidance. the Stock Sinks.

Wegovy-Maker Novo Nordisk Raises Full-Year Guidance as Appetite for Weight-Loss Drugs Grows

Novo Nordisk Lifts 2026 Outlook After Strong Q2 Adjusted Results

Novo Nordisk Q2 Lifts FY Guidance on Stronger GLP-1 Demand

Novo Nordisk Boosts Adjusted Sales, Operating Profit Guidance for 2026

MT Newswires Live

Novo Nordisk reports Q2 adjusted sales DKK 78.49B, up 7% at CER

Novo Nordisk raises FY26 adjusted sales view to 0% to down 6% from down 4%-12%

Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Legal Inquiry Launched for Hims & Hers Health Following Share Plunge

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Novo Nordisk Earnings Seen Lower; Guidance and Wegovy Pill in Focus

Stock Markets Can't Rely on Tech to Power Gains Anymore

Novo Nordisk A/S Expected to Post Earnings of Dkk4.99 a Share - Earnings Preview

Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Simply Wall St.

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NVOH/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":25.35,"timestamp":1787601600000,"preClose":25.2397,"halted":0,"volume":499,"hourTrading":{"tag":"盘后","latestPrice":25.35,"preClose":25.35,"latestTime":"16:15 EDT","volume":8,"amount":202.8,"timestamp":1787602500256,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004370099486127105,"floatShares":160001,"shares":160001,"eps":0,"marketStatus":"Not Yet Opened","change":0.1103,"latestTime":"08-24 16:00:00 EDT","open":25.33,"high":25.35,"low":25.33,"amount":12632,"amplitude":0.000792,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":25.2397,"nav":25.208606,"aum":4033402.168606,"dividendRate":0.066907,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.35,"preClose":25.35,"latestTime":"16:15 EDT","volume":8,"amount":202.8,"timestamp":1787602500256,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.570808,"impliedVol":0.111,"impliedVolPercentile":0.1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":160001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.570808,"shares":160001,"dividePrice":1.6961,"high":25.35,"amplitude":0.000792,"preClose":25.2397,"low":25.33,"week52Low":19,"pbRate":"--","week52High":34.36,"institutionHeld":0,"latestPrice":25.35,"eps":0,"divideRate":0.066907,"volume":499,"delay":0,"ttmEps":0,"open":25.33,"prevYearClose":27.4362,"prevWeekClose":25.2397,"prevMonthClose":25.407,"prevQuarterClose":26.0576,"fiveDayClose":24.4193,"twentyDayClose":27.1084,"sixtyDayClose":25.1269},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"NVOH","amount":0.76666,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"NVOH","amount":0.27495,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.27495,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.76666,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657602475","title":"Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657602475","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657602475?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:03","pubTimestamp":1785881004,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60935766/novo-nordisk-q2-adj-eps-0-96-beats-0-81-estimate-sales-12-209b-beat-11-350b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","NVOH","IE00BKVL7J92.USD","NVO","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","OZEM","BK4585","NVOX","BK4588","PPH","BK4007","LU1093756168.USD","LU1093756325.SGD","THNR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657856060","title":"NYSE Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2657856060","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657856060?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:44","pubTimestamp":1785879840,"startTime":"0","endTime":"0","summary":"Chipotle Mexican Grill       CMG    51,626,053     33.82    -3.64     -9.72. Nu Holdings Cl A              NU    51,531,649     14.33    -0.11     -0.76. Novo Nordisk ADR             NVO    47,268,475     44.28    -2.81     -5.97. Blue Owl Capital             OWL    33,762,307     11.57     0.41      3.67","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","SG9999001176.SGD","BK4592","BK4543","IE00B19Z3B42.SGD","LU0306806265.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU1861558580.USD","NVO","NYSE","LU0289739699.SGD","BK4585","BK4007","BK4581","BK4532","NVOX","LU0321505439.SGD","LU0170899867.USD","PPH","BK4588","AMC","LU0058720904.USD","LU0234572021.USD","BK4108","NVOH","LU1894683264.USD","PATX","SG9999003800.SGD","PFE","SG9999002224.SGD","LU2596442595.SGD","LU1093756168.USD","BK4097","LU0306807586.USD","BK4550","IE00BLSP4452.SGD","LU1894683348.USD","BK4568","PATH","LU1861559042.SGD","IE00BZ1G4Q59.USD","LU0456855351.SGD","BK4534","LU0985481810.HKD","OZEM","BK4539","THNR","LU1057294990.SGD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657353569","title":"The Wegovy Pill's 'surprise Miss' is One Reason Novo Nordisk's Stock is Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2657353569","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657353569?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"The pill is key to Novo's weight-loss franchise. The stock dropped 5.5% on Tuesday afternoon.Novo Nordisk's new Wegovy pill had about $500 million in sales in the second quarter, although sales came i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4599","LU0154236417.USD","NVOH","BK4532","OZEM","LU1093756168.USD","BK4585","NVOX","PPH","BK4588","IE00BKVL7J92.USD","BK4007","NVO","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171664678","title":"Wegovy Maker Novo Nordisk Lifts Annual Forecast Amid Rising Demand for Weight-Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1171664678","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171664678?lang=en_us&edition=fundamental","pubTime":"2026-08-05 03:01","pubTimestamp":1785870092,"startTime":"0","endTime":"0","summary":"Novo-Nordisk A/S has raised its full-year guidance, citing sustained demand for weight-loss medications with no signs of slowing. The Danish pharmaceutical company now expects adjusted sales and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","PPH","LU1093756325.SGD","BK4007","OZEM","BK4532","BK4599","NVOH","NVOX","NVO","LU0154236417.USD","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563216","title":"Novo Nordisk Raises Earnings Guidance. the Stock Sinks.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563216?lang=en_us&edition=fundamental","pubTime":"2026-08-05 02:16","pubTimestamp":1785867360,"startTime":"0","endTime":"0","summary":"Novo Nordisk's U.S.-listed shares sank on Tuesday after the drugmaker released its second-quarter earnings a day early.The stock slumped 6.1%. The benchmark S&P 500 index rose 1.9%.Novo reported that ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","BK4532","THNR","LU0154236417.USD","BK4588","NVO","NVOH","OZEM","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","BK4585","IE00BKVL7J92.USD","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631005","title":"Wegovy-Maker Novo Nordisk Raises Full-Year Guidance as Appetite for Weight-Loss Drugs Grows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631005","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631005?lang=en_us&edition=fundamental","pubTime":"2026-08-05 02:05","pubTimestamp":1785866700,"startTime":"0","endTime":"0","summary":"Novo Nordisk said annual sales and operating profit should fall less than it previously expected as demand for weight-loss drugs shows no sign of abating.The Danish drugmaker said it expected sales an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","NVOH","NVOX","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","PPH","BK4585","BK4007","OZEM","LU1093756168.USD","THNR","BK4532","LU0154236417.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631885","title":"Novo Nordisk Lifts 2026 Outlook After Strong Q2 Adjusted Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631885","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631885?lang=en_us&edition=fundamental","pubTime":"2026-08-05 01:57","pubTimestamp":1785866244,"startTime":"0","endTime":"0","summary":"Novo Nordisk ( ($NVO) ) has issued an update. Novo Nordisk reported its adjusted financial performance for the second quarter of 2026 on 4 August 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-lifts-2026-outlook-after-strong-q2-adjusted-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-lifts-2026-outlook-after-strong-q2-adjusted-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1093756168.USD","OZEM","IE00BKVL7J92.USD","NVO","LU1093756325.SGD","NVOH","PPH","THNR","BK4585","BK4599","BK4532","IE00BZ1G4Q59.USD","BK4007","NVOX","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568525","title":"Novo Nordisk Q2 Lifts FY Guidance on Stronger GLP-1 Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568525","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568525?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:51","pubTimestamp":1785862260,"startTime":"0","endTime":"0","summary":"Novo Nordisk Q2 lifts FY guidance on stronger GLP-1 demandOverviewDenmark healthcare firm's Q2 adjusted sales rose 7% at CER, driven by GLP-1 volume growthReported Q2 operating profit fell 16% at CER ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N4410VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4585","LU0154236417.USD","NVOX","OZEM","PPH","BK4532","IE00BZ1G4Q59.USD","BK4007","BK4588","THNR","LU1093756325.SGD","BK4599","NVO","NVOH","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685495","title":"Novo Nordisk Boosts Adjusted Sales, Operating Profit Guidance for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685495","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657685495?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:45","pubTimestamp":1785861923,"startTime":"0","endTime":"0","summary":"Price: 45.79, Change: -1.30, Percent Change: -2.76","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOX","BK4599","LU1093756325.SGD","THNR","BK4585","LU0154236417.USD","IE00BKVL7J92.USD","NVOH","BK4532","BK4007","NVO","PPH","IE00BZ1G4Q59.USD","BK4588","OZEM","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657856837","title":"Novo Nordisk reports Q2 adjusted sales DKK 78.49B, up 7% at CER","url":"https://stock-news.laohu8.com/highlight/detail?id=2657856837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657856837?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:40","pubTimestamp":1785861632,"startTime":"0","endTime":"0","summary":"Reports Q2 adjusted operating profit DKK 33.39B, up 11% CER. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-reports-q2-adjusted-sales-dkk-78-49b-up-7-at-cer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-reports-q2-adjusted-sales-dkk-78-49b-up-7-at-cer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4585","NVOX","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","NVOH","LU1093756325.SGD","PPH","THNR","BK4588","OZEM","BK4599","LU0154236417.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568352","title":"Novo Nordisk raises FY26 adjusted sales view to 0% to down 6% from down 4%-12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568352","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568352?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:40","pubTimestamp":1785861625,"startTime":"0","endTime":"0","summary":"Adjusted sales growth for 2026 is now expected to be 0% to -6% at CER and adjusted operating profit growth is now expected to be 0% to -6% at CER.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-raises-fy26-adjusted-sales-view-to-0-to-down-6-from-down-4-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-raises-fy26-adjusted-sales-view-to-0-to-down-6-from-down-4-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4532","LU1093756325.SGD","THNR","NVO","BK4588","IE00BKVL7J92.USD","LU1093756168.USD","PPH","NVOX","BK4599","BK4585","NVOH","OZEM","LU0154236417.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568311","title":"Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568311?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:31","pubTimestamp":1785861082,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S is running a real‑world database study called “Database L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-probes-thyroid-cancer-risk-in-realworld-glp1-users?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-probes-thyroid-cancer-risk-in-realworld-glp1-users?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","NVOH","THNR","BK4007","OZEM","NVOX","BK4599","IE00BKVL7J92.USD","NVO","PPH","BK4585","LU1093756168.USD","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656855745","title":"Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2656855745","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656855745?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:57","pubTimestamp":1785855446,"startTime":"0","endTime":"0","summary":"An announcement from Novo Nordisk ( ($NVO) ) is now available. Novo Nordisk A/S reported progress on its previously announced share repurchase prog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4599","NVO","NVOH","OZEM","LU1093756325.SGD","BK4532","THNR","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","PPH","BK4588","LU0154236417.USD","LU1093756168.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179166516","title":"Legal Inquiry Launched for Hims & Hers Health Following Share Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=1179166516","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179166516?lang=en_us&edition=fundamental","pubTime":"2026-08-04 03:40","pubTimestamp":1785786024,"startTime":"0","endTime":"0","summary":"A legal investigation has been initiated against Hims & Hers Health (NYSE: HIMS) by the law firm Kessler Topaz Meltzer & Check, LLP. The probe is being conducted on behalf of investors to determine...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGIA","BK4532","PPH","LU0154236417.USD","BK4588","NVO","NVOH","OZEM","THNR","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","BK4585","IE00BKVL7J92.USD","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656081013","title":"Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2656081013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656081013?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:02","pubTimestamp":1785772920,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B shed 1.4% to DKK302.30 Monday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,684.92.This was the stock's third consecutive day of losses.The company closed DKK107.65 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,028,621, compared to the 50-day average trading volume of 4,736,486.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","BK4532","THNR","LU0154236417.USD","BK4588","NVO","NVOH","OZEM","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","BK4585","IE00BKVL7J92.USD","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656437450","title":"Novo Nordisk Earnings Seen Lower; Guidance and Wegovy Pill in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2656437450","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656437450?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:18","pubTimestamp":1785763080,"startTime":"0","endTime":"0","summary":"Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what to know:PROFIT FORECAST: Net profit is expected to fall 17% to 21.88 billion Danish kroner ($3.37 billion)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVOH","THNR","OZEM","PPH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4599","LU1093756168.USD","LU1093756325.SGD","NVOX","BK4585","BK4007","NVO","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656378216","title":"Stock Markets Can't Rely on Tech to Power Gains Anymore","url":"https://stock-news.laohu8.com/highlight/detail?id=2656378216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656378216?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:45","pubTimestamp":1785753900,"startTime":"0","endTime":"0","summary":"valued at 35 times estimated 2026 sales, led by the world's richest. human. Cantor Fitzgerald's Colin Canfield characterized this first","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1127390331.HKD","LU0316494557.USD","SG9999017495.SGD","SPCH","LU0353189680.USD","IE00BFSS8Q28.SGD","BK4614","LU0823434583.USD","ILDR","LU0234572021.USD","LU0122379950.USD","BK4575","LU1989764664.SGD","LU1548497426.USD","SGXZ57979304.SGD","LU2746668461.USD","GB00BDT5M118.USD","SG9999015952.SGD","LU0820561818.USD","IE00B2B36J28.USD","LU1712237335.SGD","LU2468319806.SGD","IE00BJLML261.HKD","LU2098885051.SGD","BK4585","LEGR","LU0320765059.SGD","SG9999015986.USD","IE00BKPKM429.USD","LU2089283258.USD","LU2896262040.SGD","LU0154236417.USD","LU0889565916.HKD","LU2108987350.USD","LU1989772840.SGD","BK4612","LU0889565833.HKD","LU2265009873.SGD","IE00BK4W5M84.HKD","USXF","CNAV","LU0689472784.USD","WSPC","BK4533","LU0708995401.HKD","IE00BWXC8680.SGD","LU2462591350.SGD","SGXZ81514606.USD","LU0385154629.USD","LU0096364046.USD","LLYZ","LU1242518931.SGD","AMDU","IE00BFTCPJ56.SGD","SG9999013999.USD","LU0820561909.HKD","CANC","LU0109394709.USD","LU0432979614.USD","SG9999015978.USD","LU2237443622.USD","MARS","LU0471298777.SGD","WARP","LU1366192091.USD","LU0109391861.USD","LU1814569148.SGD","LU1989771016.USD","LU0642271901.SGD","LU2089284900.SGD","TTEQ","IE00BN29S564.USD","BK4543","LU0719512351.SGD","LU2213496289.HKD","LU0174119429.USD","LU0683600562.USD","AMDG","AMUU","LU1280957306.USD","SPAX","LU2552382215.SGD","LU1983299246.USD","XNTK","LU2028103732.USD","LU0158827781.USD","SG9999001176.SGD","LU1551013342.USD","LU0353189763.USD","TRUH","CHPS","LU2357305700.SGD","LU0056508442.USD","LU0823421416.USD","LU0390134368.USD","LU1267930730.SGD","LU0114720955.EUR","LU2271345857.HKD","AIS","LU2237443978.SGD","LU2237438978.USD","SPCX","LU0238689110.USD","LU2552382132.HKD","IE00BJJMRX11.SGD","LU0251132253.USD","LU2242649171.HKD","AMDW","IE00B775H168.HKD","LU2111349929.HKD","LU0006306889.USD","AGNG","LU2089984988.USD","NVO","LU0198837287.USD","LU1861559042.SGD","LU2355687059.USD","IE0004445239.USD","CURE","LU1868836591.USD","LU0097036916.USD","LU2361044865.SGD","AMDD","LU1323610961.USD","GDOC","MHIP","SG9999018857.SGD","NVOH","ORBX","SG9999014906.USD","CHAT","LU2361044949.HKD","IE00BMPRXQ63.HKD","FHLC","PPH","IETC","LU2462157665.USD","LU1917777945.USD","SG9999014880.SGD","LU2237443465.HKD","AMDL","LU2236285917.USD","LU2458330243.SGD","LU1232071149.USD","IE00BKVL7J92.USD","LU2456880835.USD","LU2168564495.EUR","LU1551013425.SGD","LU2458330169.SGD","AMYY","LU2237443382.USD","LU0061475181.USD","LU1720051017.SGD","LU0274383776.USD","BK4007","BK4588","LLII","LU1989772923.USD","IE00BJT1NW94.SGD","LU2471134879.HKD","BK4554","SOXY","SGXZ31699556.SGD","WISE","LU2360107168.USD","LU0127658192.USD","IE00B5949003.HKD","LU2168564149.EUR","IE00B4R5TH58.HKD","TRFK","IE00BJJMRZ35.SGD","PSI","RXL","LU2491050154.USD","LU1803068979.SGD","LU1303367103.USD","LU2602419157.SGD","LU2168564222.USD","OZEM","LU1923623000.USD","LU1880398554.USD","LU0354030511.USD","AMD","LU0106261372.USD","LU2089985449.USD","LU0882574055.USD","LU1861220033.SGD","LU2756315318.SGD","WDNA","LU0820562030.AUD","LU0109392836.USD","LU2106854487.HKD","LU1145028129.USD","SOXX","LLYX","IE0004445015.USD","NVOX","SPCF","ARTY","BK4516","LU2247934214.USD","LU0203202063.USD","SGXZ51526630.SGD","IE00B1BXHZ80.USD","LU0979878070.USD","LU1979441026.SGD","BK4532","LU2361045086.USD","LU1951200564.SGD","LU2023251221.USD","LU1064131342.USD","LU2756315664.SGD","LU0672654240.SGD","LU0320765992.SGD","LU2360106780.USD","LU2290526834.HKD","LU1868836914.USD","IE00BQXX3C00.GBP","BK4581","SG9999015945.SGD","LU0823416689.USD","LU0640476718.USD","SMHX","BK4566","LU0417517546.SGD","LU1267930813.SGD","LOFF","IE00B4JS1V06.HKD","IE00BK4W5L77.USD","XLV","ELIS","LU1093756168.USD","LU2237443895.HKD","SPCM","VHT","LU0266013472.USD","LU2931357623.SGD","LU1868837300.USD","LU0203201768.USD","LU0094547139.USD","LU1804176565.USD","GAMR","LU2552382058.USD","LU1035775433.USD","LU2461242641.AUD","IE00B1XK9C88.USD","LU0889566641.SGD","LU2324357040.USD","BAI","BK4529","LU0323591593.USD","LU1989764748.USD","AMDY","SPCQ","TEK","LU1291159041.SGD","IYH","LU1951198990.SGD","LU1061106388.HKD","HRTS","LU2112291526.USD","LU2023250330.USD","THNR","AMDS","LU0225283273.USD","LU1069344957.HKD","IE00BFSS7M15.SGD","BK4512","LU0792757196.USD","QQQA","IE0009355771.USD","LU1057294990.SGD","LU2491050071.SGD","LU0256863902.USD","LU0786609619.USD","MEDI","MEDX","AIQ","LU1623119135.USD","LU0210536198.USD","LU0345770308.USD","SGXZ99366536.SGD","LU2417539215.USD","LU2168564065.EUR","LU0823421333.USD","LU1242518857.USD","DAMD","LU0456855351.SGD","LU1023059063.AUD","LU2250418816.HKD","SPCG","ELIL","IE0005OL40V9.USD","LU1988902786.USD","BK4534","LU0964807845.USD","LU1093756325.SGD","LU0133085943.USD","FTXH","LU0787776722.HKD","BK4573","LLY","LU0256863811.USD","LU2087625088.SGD","IE0009356076.USD","LU2471134523.USD","FAI","IE0002141913.USD","BK4141","SG9999018865.SGD","LU2063271972.USD","LU0048584097.USD","SG9999001424.SGD","LU2491049909.HKD","LU2746668974.SGD","LU2750360641.GBP","LU2168563687.JPY","IE00BQXX3D17.EUR","TMED","BK4605","IE00BMPRXR70.SGD","IE00BJJMRY28.SGD","LU0471298694.HKD","LU1974910355.USD","LU2023250504.SGD","WUGI","LU1880398471.USD","LU1629891620.HKD","LU0158827948.USD","LU2211815571.USD","JDOC","IE00BQXX3F31.USD","LU2750360997.AUD","SSPC","LU2264538146.SGD","SMH","IXJ","LU0079474960.USD","BK4089","LU0345770993.USD","LU2360106947.USD","LU0466842654.USD","LU2471134796.USD","LU1868837136.USD","LU1861558580.USD","IE0001KFT4U8.USD","LU0289739699.SGD","LU0354030438.USD","LU0943347566.SGD","LU0082616367.USD","PJP","SG9999001176.USD","SG9999014898.SGD","LU1868836757.USD","IE00B7KXQ091.USD","LU2860962120.EUR","LU0081259029.USD","FTXL","IE00BKDWB100.SGD","LU1316542783.SGD","BK4599","IE00BMPRXN33.USD","LU0058720904.USD","LU2237443549.SGD","IHE","LU1852331112.SGD","SG9999014914.USD","LU2054465674.USD","IE00BZ1G4Q59.USD","LU2471134952.CNY","LU1720051108.HKD","LU1861215975.USD","LU0882574139.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656328344","title":"Novo Nordisk A/S Expected to Post Earnings of Dkk4.99 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656328344","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656328344?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:36","pubTimestamp":1785735367,"startTime":"0","endTime":"0","summary":"Novo Nordisk A/S <NVO.N> expected to post earnings of DKK4.99 a share - Earnings PreviewNovo Nordisk A/SNVO.N,NVOis expected to  show a fall in quarterly revenue when it reports  results on August 5 f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N44005A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","BK4588","LU0154236417.USD","OZEM","IE00BKVL7J92.USD","PPH","LU1093756325.SGD","NVOH","NVO","LU1093756168.USD","BK4532","THNR","BK4007","BK4599","IE00BZ1G4Q59.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656731916","title":"Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656731916","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656731916?lang=en_us&edition=fundamental","pubTime":"2026-08-02 03:19","pubTimestamp":1785611958,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NYSE:NVO) reported that its late stage ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease and chronic kidney disease did not show a statistically significant clinical benefit.\nThe company said the trial still showed evidence of biological target engagement but will book a non cash impairment linked to the asset.\nNovo Nordisk confirmed that it plans to continue its research efforts in cardiovascular disease despite the ZEUS outcome.\n\nNovo Nordisk,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-ziltivekimab-trial-fails-in-late-stage","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-ziltivekimab-trial-fails-in-late-stage","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","LU0154236417.USD","BK4532","LU1093756168.USD","THNR","BK4588","IE00BZ1G4Q59.USD","LU1093756325.SGD","OZEM","BK4585","NVOH","IE00BKVL7J92.USD","PPH","NVO","NVOX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656239478","title":"Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2656239478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656239478?lang=en_us&edition=fundamental","pubTime":"2026-08-01 06:18","pubTimestamp":1785536326,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed a major Phase 3 c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/is-novo-nordisk-stock-nvo-a-good-buy-after-todays-plunge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/is-novo-nordisk-stock-nvo-a-good-buy-after-todays-plunge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","NVOH","BK4599","BK4007","BK4588","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","THNR","IE00BKVL7J92.USD","LU0154236417.USD","BK4585","BK4532","OZEM","PPH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}